본문바로가기
About Us
SK bioscience
Company Overview
History
Vision
Contact Us
Leadership
CEO Message
Headquarters & Facilities
Global R&PD Center
L HOUSE
Subsidiary
SK bioscience USA
IDT Biologika
Science & Technology
Pipeline
R&D
Production
Business
Business Overview
Domestic
Overseas Business
Vaccine Co-Development
and Technology Transfer
CDMO/CMO
Products
In-house Products
Outsourced Products
Global Partnerships
ESG
새창열기 아이콘
IR
Corporate Governance
Company Information
Financial Information
Financial Statements
Financial Credit
Audit Reports
Investment Information
Stock Prices
Shareholder Status
IR Documents
Disclosure
PR
Press Releases
Media Zoom
Brochure
CI Guideline
KOR
ENG
sitemap
About Us
SK bioscience
Company Overview
History
Vision
Contact Us
Leadership
CEO Message
Headquarters & Facilities
Global R&PD Center
L HOUSE
Subsidiary
SK bioscience USA
IDT Biologika
Science
& Technology
Pipeline
R&D
Production
Business
Business Overview
Domestic
Overseas Business
Vaccine Co-Development
and Technology Transfer
CDMO/CMO
Products
In-house Products
Outsourced Products
Global Partnerships
ESG
새창열기 아이콘
IR
Corporate Governance
Company Information
Financial Information
Financial Statements
Financial Credit
Audit Reports
Investment Information
Stock Prices
Shareholder Status
IR Documents
Disclosure
PR
Press Releases
Media Zoom
Brochure
CI Guideline
PR
SK bioscience company news updates
PR
About Us
Science & Technology
Business
ESG
IR
PR
Press Releases
Press Releases
Media Zoom
Brochure
CI Guideline
Press releases
SK bioscience Strengthens Global Pandemic Preparedness through Participation in Korea’s “100 Days Mission” Simulation Exercise
2026.02.05
SK bioscience Announces Preliminary FY2025 Results 2.4x Revenue Growth Year-over-Year Driven by IDT Turnaround and Strong Vaccine Sales
2026.02.03
SK bioscience In-Licenses RSV Preventive mAb Candidate from Gates Medical Research Institute
2026.02.03
SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family
2026.01.29
SK bioscience, MSD, and Hilleman Laboratories Advance Zaire ebolavirus Vaccine Development with CEPI Funding
2026.01.22
SK bioscience Marks the Start of Its “Songdo Era” Global R&PD Center Begins Operations as a New Global Innovation Hub
2026.01.19
SK bioscience and Sanofi Launch MenQuadfi Meningococcal Vaccine in Korea
2026.01.09
SK bioscience Earns ‘A’ Rating in KCGS ESG Assessment for Fourth Consecutive Year
2025.11.19
IDT Biologika Accelerates Global CDMO Expansion Manufacturing capabilities highlighted through consecutive participation in WVC, CPHI and BIO-Europe 2025
2025.11.05
SK bioscience strengthens global vaccine partnerships to expand R&D pipeline competitiveness
2025.10.29
처음
이전
1
2
3
4
5
6
7
8
9
10
다음
끝
